Publication record - Circulating Cancer Biomarkers team.
2015
1.
Saliou A, Bidard FC, Lantz O, Stern MH, Vincent-Salomon A, Proudhon C, Pierga JY.
Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment
decisions. Expert Rev Mol Diagn. 2015 Nov 15. [Epub ahead of print].
2.
Bidard FC, Ng CK, Cottu P, Piscuoglio S, Escalup L, Sakr RA, Reyal F, Mariani P, Lim
R, Wang L, Norton L, Servois V, Sigal B, Vincent-Salomon A, Weigelt B, Pierga JY,
Reis-Filho JS. Response to dual HER2 blockade in a patient with HER3-mutant
metastatic breast cancer. Ann Oncol. 2015 Aug;26(8):1704-9.
3.
Bidard FC, Pierga JY. Clinical utility of circulating tumor cells in metastatic breast
cancer. J Clin Oncol. 2015 May 10;33(14):1622.
4.
Autebert J, Coudert B, Champ J, Saias L, Guneri ET, Lebofsky R, Bidard FC, Pierga
JY, Farace F, Descroix S, Malaquin L, Viovy JL. High purity microfluidic sorting and
analysis of circulating tumor cells: towards routine mutation detection. Lab Chip. 2015
May 7;15(9):2090-101.
5.
Helissey C, Berger F, Cottu P, Diéras V, Mignot L, Servois V, Bouleuc C, Asselain B,
Pelissier S, Vaucher I, Pierga JY, Bidard FC. Circulating tumor cell thresholds and
survival scores in advanced metastatic breast cancer: the observational step of the
CirCe01 phase III trial. Cancer Lett. 2015 May 1;360(2):213-8.
6.
Madic J, Kiialainen A, Bidard FC, Birzele F, Ramey G, Leroy Q, Rio Frio T, Vaucher I,
Raynal V, Bernard V, Lermine A, Clausen I, Giroud N, Schmucki R, Milder M, Horn C,
Spleiss O, Lantz O, Stern MH, Pierga JY, Weisser M, Lebofsky R. Circulating tumor
DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J
Cancer. 2015 May 1;136(9):2158-65.
7.
Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, Leroy Q, Rio Frio T, Pierron G,
Callens C, Bieche I, Saliou A, Madic J, Rouleau E, Bidard FC, Lantz O, Stern MH, Le
Tourneau C, Pierga JY. Circulating tumor DNA as a non-invasive substitute to
metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial
across all tumor types. Mol Oncol. 2015 Apr;9(4):783-90.
8.
Pierga JY, Petit T, Lévy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H,
Bachelot T, Charafe-Jauffret E, Bonneterre J, Hernandez J, Bidard FC, Viens P.
Pathological response and circulating tumor cell count identifies treated HER2+
inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data.
Clin Cancer Res. 2015 Mar 15;21(6):1298-304.
9.
Ng CK, Schultheis AM, Bidard FC, Weigelt B, Reis-Filho JS. Breast cancer genomics
from microarrays to massively parallel sequencing: paradigms and new insights. J Natl
Cancer Inst. 2015 Feb 23;107(5).
10. Perez-Toralla K, Mottet G, Guneri ET, Champ J, Bidard FC, Pierga JY, Klijanienko J,
Draskovic I, Malaquin L, Viovy JL, Descroix S. FISH in chips: turning microfluidic
fluorescence in situ hybridization into a quantitative and clinically reliable molecular
diagnosis tool. Lab Chip. 2015 Feb 7;15(3):811-22.
2014
1.
Llombart-Cussac A, Pivot X, Biganzoli L, Cortes-Funes H, Pritchard KI, Pierga JY, Smith
I, Thomssen C, Srock S, Sampayo M, Cortes J. A prognostic factor index for overall
survival in patients receiving first-line chemotherapy for HER2-negative advanced breast
cancer: an analysis of the ATHENA trial. Breast. 2014 Oct;23(5):656-62.
2.
Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S,
Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi
R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-
Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E,
Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki
S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K,
Pierga JY, Michiels S. Clinical validity of circulating tumour cells in patients with
metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol.
2014 Apr;15(4):406-14.
3.
Bidard FC, Madic J, Mariani P, Piperno-Neumann S, Rampanou A, Servois V, Cassoux
N, Desjardins L, Milder M, Vaucher I, Pierga JY, Lebofsky R, Stern MH, Lantz O.
Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA
in metastatic uveal melanoma: Circulating Tumor DNA in Uveal Melanoma. Int J
Cancer. 2014 Mar 1;134(5):1207-13.
2013
1.
Pierga JY, Bidard FC, Cropet C, Tresca P, Dalenc F, Romieu G, Campone M, Mahier
Aït-Oukhatar C, Le Rhun E, Gonçalves A, Leheurteur M, Dômont J, Gutierrez M, Curé H,
Ferrero JM, Labbe-Devilliers C, Bachelot T. Circulating tumor cells and brain metastasis
outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial. Ann
Oncol. 2013 Dec;24(12):2999-3004.
2.
Bidard FC, Huguet F, Louvet C, Mineur L, Bouché O, Chibaudel B, Artru P, Desseigne
F, Bachet JB, Mathiot C, Pierga JY, Hammel P. Circulating tumor cells in locally
advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.
Ann Oncol. 2013 Aug;24(8):2057-61.
3.
Ligthart ST, Coumans FA, Bidard FC, Simkens LH, Punt CJ, de Groot MR, Attard G, de
Bono JS, Pierga JY, Terstappen LW. Circulating Tumor Cells Count and Morphological
Features in Breast, Colorectal and Prostate Cancer. PLoS One. 2013 Jun
27;8(6):e67148.
4.
Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabières C, Janni W, Messina C,
Paoletti C, Müller V, Hayes DF, Piccart M, Pierga JY. Clinical application of circulating
tumor cells in breast cancer: overview of the current interventional trials. Cancer
Metastasis Rev. 2013 Jun;32(1-2):179-88.
5.
Ligthart ST, Bidard FC, Decraene C, Bachelot T, Delaloge S, Brain E, Campone M,
Viens P, Pierga JY, Terstappen LW. Unbiased quantitative assessment of Her-2
expression of circulating tumor cells in patients with metastatic and non-metastatic
breast cancer. Ann Oncol. 2013 May;24(5):1231-8.
6.
Giordano A, Egleston BL, Hajage D, Bland J, Hortobagyi GN, Reuben JM, Pierga JY,
Cristofanilli M, Bidard FC. Establishment and Validation of Circulating Tumor Cell-Based
Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients. Clin Cancer
Res. 2013 Mar 15;19(6):1596-602.
7.
Bidard FC, Pierga JY, Soria JC, Thiery JP. Translating metastasis-related biomarkers to
the clinic--progress and pitfalls. Nat Rev Clin Oncol. 2013 Mar;10(3):169-79.
8.
Bidard FC, Belin L, Delaloge S, Lerebours F, Ngo C, Reyal F, Alran S, Giacchetti S,
Marty M, Lebofsky R, Pierga JY. Time-Dependent Prognostic Impact of Circulating
Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the
REMAGUS02 Study. Int J Breast Cancer. 2013;2013:130470.
2012
1.
Campitelli M, Jeannot E, Peter M, Lappartient E, Saada S, de la Rochefordière A,
Fourchotte V, Alran S, Petrow P, Cottu P, Pierga JY, Lantz O, Couturier J, SastreGarau X. Human Papillomavirus Mutational Insertion: Specific Marker of Circulating
Tumor DNA in Cervical Cancer Patients. PLoS One. 2012;7(8):e43393.
2.
Madic J, Piperno-Neumann S, Servois V, Rampanou A, Milder M, Trouiller B, Gentien
D, Saada S, Assayag F, Thuleau A, Nemati F, Decaudin D, Bidard FC, Desjardins L,
Mariani P, Lantz O, Stern MH. Pyrophosphorolysis-Activated Polymerization Detects
Circulating Tumor DNA in Metastatic Uveal Melanoma. Clin Cancer Res. 2012 Jul
15;18(14):3934-41.